Reduction in All-Cause Mortality With Fluticasone Furoate/Umeclidinium/Vilanterol in COPD Patients

American Journal of Respiratory and Critical Care Medicine - United States
doi 10.1164/rccm.201911-2207oc
Full Text
Abstract

Available in full text

Date
Authors
Publisher

American Thoracic Society

Related search

Single-Inhaler Triple Therapy Utilizing the Once-Daily Combination of Fluticasone Furoate, Umeclidinium and Vilanterol in the Management of COPD: The Current Evidence Base and Future Prospects

Therapeutic Advances in Respiratory Disease
PulmonaryRespiratory MedicinePharmacology
2018English

Evidence-Based Review of Data on the Combination Inhaler Umeclidinium/Vilanterol in Patients With COPD

International Journal of COPD
EnvironmentalPublic HealthHealth PolicyMedicinePulmonaryRespiratory MedicineOccupational Health
2019English

A Randomised Trial of Fluticasone Furoate/Vilanterol (50/25 Μg; 100/25 Μg) on Lung Function in COPD

Respiratory Medicine
PulmonaryRespiratory Medicine
2013English

A Comparison of the Efficacy and Safety of Once-Daily Fluticasone Furoate/Vilanterol With Twice-Daily Fluticasone Propionate/Salmeterol in Moderate to Very Severe COPD

European Respiratory Journal
MedicinePulmonaryRespiratory Medicine
2013English

Cost–consequence Analysis of Fluticasone Furoate/Vilanterol 92/22 MCG for the Management of COPD in the Spanish NHS

ClinicoEconomics and Outcomes Research
Health PolicyEconomicsEconometricsFinance
2018English

Prs48 - Cost – Effectiveness Analysis of Vilanterol/Fluticasone Furoate for Asthma Treatment in the Russian Federation

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Fluticasone Furoate/Vilanterol Once Daily Improves Night-Time Awakenings in Asthma Patients With Night Symptoms; Post-Hoc Analyses of Three Randomized Controlled Trials

Journal of Asthma
Child HealthAllergyPerinatologyImmunologyMedicinePediatricsPulmonaryRespiratory Medicine
2018English

Patient Considerations in the Treatment of COPD: Focus on the New Combination Inhaler Umeclidinium/Vilanterol

Patient Preference and Adherence
PharmacologyHealth PolicyMedicineToxicologySocial SciencesPharmaceutics
2015English

Corrigendum to “Fluticasone Furoate/Vilanterol (100/25; 200/25 Μg) Improves Lung Function in COPD: A Randomised Trial” [Respir Med 107 (2013) 550–559]

Respiratory Medicine
PulmonaryRespiratory Medicine
2013English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy